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Abstract
Background: Typhoid fever mainly occurs in (sub) tropical regions where sanitary conditions remain poor. In other
regions it occurs mainly among returning travelers or their direct contacts. The aim of this study was to evaluate
the current Dutch guidelines for typhoid vaccination.
Method: Crude annual attack rates (AR) per 100,000 Dutch travelers were calculated during the period 1997 to
2014 by dividing the number of typhoid fever cases by the estimated total number of travelers to a specific country
or region. Regions of exposure and possible risk factors were evaluated.
Results: During the study period 607 cases of typhoid fever were reported. Most cases were imported from Asia
(60%). Almost half of the cases were ethnically related to typhoid risk regions and 37% were cases visiting friends
and relatives. The overall ARs for travelers to all regions declined significantly. Countries with the highest ARs were
India (29 per 100,000), Indonesia (8 per 100,000), and Morocco (10 per 100,000). There was a significant decline in
ARs among travelers to popular travel destinations such as Morocco, Turkey, and Indonesia. ARs among travelers to
intermediate-risk areas according to the Dutch guidelines such as Latin America or Sub-Saharan Africa remained
very low, despite the restricted vaccination policy for these areas compared to many other guidelines.
Conclusion: The overall AR of typhoid fever among travelers returning to the Netherlands is very low and has
declined in the past 20 years. The Dutch vaccination policy not to vaccinate short-term travelers to Latin-America,
Sub-Saharan Africa, Thailand and Malaysia seems to be justified, because the ARs for these destinations remain very
low. These results suggest that further restriction of the Dutch vaccination policy is justified.
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Background
Typhoid fever is caused by the bacteria Salmonella
enterica subspecies enterica serovar Typhi (S. Typhi)
and is primarily spread through the fecal-oral route.
Symptoms usually develop 1–3 weeks after exposure,
may be mild to severe, and include high fever, malaise,
headache, constipation or diarrhea, rose-coloured spots
on the chest, and enlarged spleen and liver [1, 2]. The
estimated number of typhoid cases in low and middle
income countries is around 20 million cases and 223,000
deaths occur worldwide every year [3–7]. The burden of
disease occurs mainly in (sub) tropical regions where
sanitary conditions remain poor. In other regions
typhoid fever mainly occurs among returning travelers
or their direct contacts [1, 2, 8]. Reliable data on the
disease burden in (sub) tropical countries is not available
since many hospitals lack facilities for blood culture and
most patients are treated as outpatients, who are not
registered [1, 9]. An earlier study found a decline in
typhoid fever attack rates (ARs) among Dutch travelers
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to these countries, most likely caused by increasing
hygienic standards since 1995 [10]. This suggests that
disease burden in (sub) tropical countries is declining as
well. Oral and parental vaccines against S. Typhi are
available. The protection of these vaccines is around
30–50% and 60–70% respectively [11].
National guidelines for typhoid vaccination for travelers
differ between countries. For example, the American
guidelines [12] (CDC) do not distinguish between high
and intermediate-risk regions, and recommend typhoid
vaccination for travelers to almost all African, Asian, and
Latin American countries, especially those visiting friends
or relatives (VFRs) or those visiting smaller cities, villages,
or rural areas. In contrast, the Canadian guidelines [13]
(CATMAT) do distinguish between high-risk regions
(South Asia) and intermediate-risk regions (Africa, most
parts of Latin America and the rest of Asia). Typhoid
vaccination is recommended for travelers to high-risk
regions and is considered for travelers to intermediate-risk
regions if there are individual-specific risk factors (e.g.,
children, VFRs, longer duration of travel). Finally, British
guidelines [14] (NaTHNaC) distinguish high (e.g., children,
long-term travelers, and VFRs) and low risk groups, as well
as high (most parts of Africa, South and South-East Asia,
and some countries in Latin America and the Middle East)
and intermediate-risk (most countries in Latin America,
the Middle East, Central Asia, Eastern Europe, and a few
countries in Africa) regions. Typhoid vaccination is recom-
mended for high-risk groups traveling to high-risk regions
and considered for high-risk groups traveling to inter-
mediate risk-regions.
The Dutch National Coordination Centre for Travellers’
Health Advice (LCR) is responsible for the national travel
medicine guidelines for the Netherlands. It is established
to improve uniformity in health advice for travelers and in
the quality of national vaccination centers. The LCR
vaccination guidelines for typhoid are based on estimates
of typhoid fever ARs among returning travelers to the
Netherlands, consensus, and other national guidelines. As
in the UK and Canada, LCR distinguishes high-risk and
intermediate-risk regions for typhoid fever (Fig. 1) and
recommends vaccination for those traveling to high-risk
regions for at least 2 weeks. Travelers going to
intermediate-risk regions are only recommended vaccin-
ation if they travel for at least 3 months or if they travel
for at least 2 weeks and have an increased risk of typhoid
fever (e.g., use antacid or have prosthetic heart valves).
Compared to other national guidelines, LCR has a
restricted vaccination policy, especially for travelers to
Latin America and Africa.
As risks of travel-related diseases are subject to change
over time, it is important to evaluate these guidelines on
Legend
high risk: typhoid vaccination is recommended for travelers going for  2 weeks or more
intermediate risk:  typhoid vaccination is recommended for travelers going for 3 months or more; or who travel for 2 weeks or more and have an increased risk of typhoid 
low risk: no typhoid vaccination is recommended
Fig. 1 High and intermediate typhoid risk areas according to LCR guidelines
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a regular basis. The aim of this study is to evaluate the
current Dutch national guidelines for typhoid vaccination
recommendations. National surveillance data on reported
typhoid fever cases and travel statistics were used to
retrospectively estimate trends in typhoid fever ARs
among travelers by geographic region.
Methods
Study population and definitions
In the Netherlands, typhoid fever is a notifiable disease.
A retrospective study was carried out based on all typhoid
fever blood culture-confirmed cases reported by the
regional Public Health Services (PHS) to the National
Institute of Public Health and the Environment
(RIVM) between 1997 and 2014. When a case is reported,
PHS collect information on patients, including basic
demographic data (age, country of birth, parents’ country
of birth), date of disease onset, related cases with typhoid
fever, travel history, reported vaccination status, and most
likely country of infection. For our study, we categorized
cases by ethnicity. If the country of birth of a case or one
of the case’s parents is a high or intermediate-risk typhoid
country, we classified the case’s ethnicity as from a
typhoid risk region. We classified cases as “visiting
friends and relatives” (VFR) if both the ethnicity of
the case and the most likely country of infection was
a typhoid risk region.
For this study, we defined ‘(sub) tropical countries’ as
a country where hepatitis A is endemic according to
WHO International Travel and Health (ITH) [15].
Statistical analysis
Crude annual attack rates (AR) per 100,000 Dutch trav-
elers were calculated by dividing the number of typhoid
fever cases by the estimated total number of travelers to
a specific country or region. For the denominator, we
used data from the Continuous Holiday Survey carried
out by the Dutch Tourist Board and NIPO research for
the period 1997 to 2014 [16]. This survey collects travel
data from a random sample of the Dutch population
four times a year. Participants complete a comprehen-
sive questionnaire related to travel and holiday destina-
tions over the telephone. The results are weighted to
represent the general Dutch population. The travel data
provides only information about the destination, it does
not provide information on duration of travel, purpose
of travel, travel circumstances, and preventive measures
taken (including vaccination).
To observe AR trends, the number of travelers each
year was smoothed using a uniformly weighted moving
average model: A new data series was generated by
adding the current observation (n), one lagged observation
(n − 1), and one forward observation (n + 1), and dividing
by three. Hence, ARs were calculated for a period of three
years.
Chi-square test for linear trend was performed in Epi
Info version 3.03a (CDC, Atlanta, GA, USA) for analyzing
time trends in AR. As country-specific travel data were
not available during the whole study period for all coun-
tries, ARs were only assessed for countries where these
data were available. Region-specific travel data were avail-
able for the whole study period and were used to analyze
trends per region. A p value <0.05 was considered statisti-
cally significant.
Results
During the study period 607 cases of typhoid fever were
reported in the Netherlands. In 12 (2%) cases the
country of exposure was unknown. Of all 607 cases,
89.3% (n = 542) were acquired in a (sub) tropical
country.
Table 1 shows the characteristics of typhoid fever cases
in the study population. The median age of the cases is
27 years (interquartile range, 15–38). Most typhoid cases
(59.6%) were imported from Asia (Fig. 2). Of all 548/607
(90.3%) cases whose vaccination status was known, 118/
548 (21.5%) reported to have been vaccinated against
typhoid fever. Every reported case in the Netherlands is
asked if they had a parental vaccination in the last three
years before the first day of disease. Only those patients
are considered to have been vaccinated.
The majority of cases with a known country of birth
(n = 384) were born in a low-risk typhoid country (n = 212,
55.2%), of whom 83 (39.2%) had a parent born in a high or
intermediate-risk typhoid country. Of 35/212 (16.5%) of
the cases born in a low-risk typhoid country, the country
of birth of both parents was unknown.
In 1997 the estimated annual number of travelers to
(sub) tropical countries was 1.1 million per 15.6 million
inhabitants (7.1%), increasing to 2.1 million per 16.9
million inhabitants in 2014 (12.4%) [16].
Table 2 shows the ARs for typhoid fever per 100,000
travelers to all regions and to the most popular travel
destinations in (sub) tropical regions from 1997 to 2014.
The overall ARs for travelers to all regions declined
significantly. ARs in travelers to Latin America were
low and did not significantly decline over time. ARs
in travelers to Sub-Saharan Africa and to the Arab re-
gion (including Turkey) declined significantly. Among
travelers to Asia, ARs were relatively high and stable
over calendar time.
Countries with the highest ARs were India, Indonesia
and Morocco. The ARs were highest among travelers to
India and there was no significant decline over time.
ARs among travelers to Morocco, Turkey, and Indonesia
significantly declined over time (Table 2). Pakistan was
among the top 5 countries of exposure in terms of
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absolute number of imported cases. Unfortunately, it
was not possible to calculate ARs for Pakistan, as no
data were available for travelers to Pakistan. There was
no data available for travelers to Surinam until
2007–2009.
Of all the cases who were VFRs and had a known
vaccination status (n = 205), only 9 (4.4%) had been
vaccinated; of all non-VFR cases with a known vaccination
status (n = 57), 17 (29.8%) had been vaccinated (p < 0.001).
Discussion
This study shows that, although the number of travelers
increased, the overall attack rate of typhoid fever among
returning travelers to the Netherlands is very low,
despite the restricted vaccination policy compared to
other countries. In India, which had the highest AR of
all travel destinations the AR has not significantly
declined over the study years. Previous studies also
found that the Indian subcontinent has the highest at-
tack rates among travelers [2, 3, 8]. The ARs in travelers
to other countries with a high AR in 1997–1999
(Morocco, Turkey, and Indonesia) have significantly
declined in recent years.
Previous Dutch colonies include Surinam, the
former Netherlands Antilles, and Indonesia. Large im-
migrant groups from these countries and from Turkey
and Morocco live in the Netherlands. These countries
are popular destinations for Dutch citizens, especially
for VFRs. LCR does not recommend typhoid vaccin-
ation for any individual traveling to the former
Netherlands Antilles. Approximately 90,000 Dutch
citizens go there each year. It is remarkable that no
typhoid cases have been imported from the former
Netherlands Antilles since 1997 although some na-
tional guidelines do recommend [12] or consider [13]
typhoid vaccination for certain travelers to the former
Netherlands Antilles.
Indonesia and India are high-risk countries accord-
ing to LCR; typhoid vaccination is recommended for
all travelers going to these countries for at least
2 weeks. The ARs in these two countries are among
the highest of all. For Indonesia, the ARs have de-
clined significantly. Twenty years ago, Indonesia had
the highest AR of all countries, however in 2014
there were approximately 106,000 Dutch travelers
going to Indonesia and only one typhoid case was
reported in a returning traveler (Table 2). In a previ-
ous study it was found that increasing hygienic and
sanitary conditions at travel destinations strongly
contributes to a decline in ARs of fecal-orally trans-
mitted diseases among visiting travelers [10]. Our
data suggest that Indonesia might now be considered
an intermediate-risk country, which is what CATMAT
already does [13].
Surinam, Turkey, and Morocco have been defined as
intermediate-risk countries according to LCR, which
means short-term travelers are not vaccinated against
typhoid. Each year on average 21,000 Dutch inhabitants
travel to Surinam, 604,000 to Turkey, and 44,000 to
Table 1 Characteristics of Dutch cases of typhoid fever
acquired in a developing country between 1997 and 2014




Median age (Interquartile range) 27 (15–38)





Latin Americab 17 2.8%
Sub-Saharan Africac 37 6.1%

















No hospitalization 97 16.0%
Hospitalization unknown 210 34.6%
Vaccination status
Vaccinated 118 19.4%19.4%
Non vaccinated 430 70.8%
Unknown 59 9.7%
aEthnicity by region: region of birth of case or one of case’s parents
bLatin America constitutes Central and South America, including the Caribbean
cSub-Saharan Africa constitutes Western, Middle, Eastern, and Southern Africa
dThe Arab region constitutes Northern Africa and Western Asia,
including Turkey
eAsia constitutes Eastern and South-Eastern Asia, and the Indian subcontinent
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Morocco. It is therefore remarkable that no
imported typhoid cases from Surinam have been re-
ported since 1997 and no imported cases have been
reported from Turkey since 2005. For Morocco, the
AR has declined significantly since 1997. As for
Turkey and Surinam, several guidelines [13, 14] rec-
ommend typhoid vaccination for risk-group travelers
to these countries, and some guidelines [12] recom-
mend typhoid vaccination for all travelers, which
might no longer be necessary.
The Dutch vaccination policy, which has not chan-
ged since 1997, not to vaccinate short-term travelers
to Latin America, Sub-Saharan Africa, Thailand, and
Malaysia seems to be justified, because the ARs for
these destinations remained very low. Thailand for
example has a median AR of 0 per 100,000 travelers
and only one traveler returning from Thailand has
been diagnosed with typhoid fever since 1997, despite
an estimated average of 70,000 travelers each year.
Although some national guidelines do not distinguish
different risk areas within Asia [12], our results show
there are large differences (e.g., between India and
Thailand), justifying a country-specific policy.
Since 2012 there have been annual vaccine shortages
for at least a number of months. The main reason for
the worldwide shortages of vaccines since 2012 were a
number of recalls by the manufacturer because the
batches produced did not meet the strict quality criteria.
Also, there has been an increase in travelers, a higher
demand and not enough vaccine in stock. During these
periods of vaccine shortages, LCR amended their
guidelines so that the limited available vaccines were
reserved for travelers at highest risk: vaccination was
temporarily advised only for those traveling for at
least 2 weeks to India, Pakistan, or Bangladesh, and
for travelers going for at least 4 weeks to other high-risk
areas. No vaccination was recommended for travelers to
intermediate-risk areas. Despite these substantial periods
of limited vaccination, we did not find any increase in
typhoid cases among returning travelers since 2012.
This might suggest that these temporal revised LCR
guidelines for typhoid fever vaccination are sufficient.
One of the limitations of our study is that the ques-
tionnaire from the Continuous Holiday Survey is in
Dutch, so only Dutch speaking citizens can participate,
limiting representativeness of our study. We might have
underestimated the annual number of travelers and thus
overestimated ARs. Unfortunately, there are no alterna-
tive estimates available.
Another limitation of our study is that neither the
travelers’ statistics [16] nor the characteristics of reported
typhoid cases provide information on duration of travel,
purpose of travel, travel circumstances, and preventive
measures taken (vaccination data is only available for
cases). Therefore it was not possible to evaluate these
travel-related risk factors for typhoid fever in travelers and
determine whether trends might also be explained by
temporal changes in these characteristics. Vaccination
is not the only important measure to prevent typhoid.
Previous studies show that risk factors for typhoid
fever include ‘not seeking pre-travel advice’, ‘not following
food and water precautions’, ‘travel to rural areas with poor
sanitation’ [17], ‘being older with a longer duration of stay’
[18], ‘a longer duration of stay in general’ [19], and ‘visiting
Fig. 2 Absolute number of imported typhoid cases in the Netherlands per travel region (1997–2014)
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Table 2 Trends in attack rates (95% confidence interval) for typhoid fever per 100,000 Dutch travelers to (sub) tropical regions from 1997 to 2014 per region/country
1997–1999 1998–2000 1999–2001 2000–2002 2001–2003 2002–2004 2003–2005 2004–2006 2005–2007
AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI)
All regions 2,79(1,95–3,98) 2,46(1,70–3,54) 2,40(1,69–3,41) 2,03(1,40–2,94) 1,81(1,24–2,65) 1,63(1,11–2,39) 1,52(1,06–2,19) 1,30(0,89–1,90) 1,17(0,79–1,74)
Latin Americac 0,39(0,07–2,24) 0,40(0,07–2,27) 0,28(0,04–2,14) 0,49(0,09–2,78) 0,16(0,01–2,10) 0,26(0,03–2,00) 0,43(0,09–2,00) 0,47(0,12–1,92) 0,36(0,08–1,68)
Netherlands Antilles 0,00(0,00–4,88) 0,00(0,00–5,91) 0,00(0,00–6,78) 0,00(0,00–9,07) 0,00(0,00–7,03) 0,00(0,00–6,03) 0,00(0,00–4,52) 0,00(0,00–4,03) 0,00(0,00–3,52)
Surinamb 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Sub-Saharan Africad 0,37(0,03–4,98) 1,21(0,21–6,85) 1,61(0,35–7,53) 2,67(0,73–9,72) 5,61(2,18–14,42)∞ 5,95(2,54–13,93)∞ 5,17(2,21–12,11)∞ 2,51(0,85–7,39) 1,29(0,32–5,24)
Arab regione 2,50(1,33–4,70) 2,02(1,07–3,79) 1,62(0,86–3,05) 0,84(0,39–1,84) 0,75(0,35–1,64) 0,70(0,33–1,50) 0,56(0,26–1,22) 0,33(0,12–0,89) 0,20(0,06–0,66)
Turkey 1,38(0,41–4,62) 0,99(0,30–3,31) 0,68(0,20–2,27) 0,21(0,04–1,17) 0,06(0,00–0,76) 0,13(0,02–0,76) 0,09(0,01–0,66) 0,09(0,01–0,67) 0,00(0,00–0,56)
Morocco 20,63(8,31–51,24) 18,48(8,29–41,19) 22,86(10,02–52,15) 15,58(6,06–40,07) 20,00(8,05–49,67) 18,57(7,48–46,12) 15,29(6,16–37,98) 7,84(2,51–24,47) 4,96(1,48–16,62)
Asiaf 5,38(3,46–8,37) 4,74(2,96–7,59) 5,00(3,23–7,76) 5,01(3,20–7,86) 4,30(2,65–6,98) 3,97(2,36–6,66) 3,98(2,48–6,41) 3,99(2,52–6,30) 4,53(2,91–7,05)
Thailand 0,00(0,00–7,39) 0,00(0,00–7,73) 0,00(0,00–7,03) 0,00(0,00–7,07) 0,51(0,04–6,86) 0,45(0,03–6,11) 0,43(0,03–5,80) 0,00(0,00–5,19) 0,00(0,00–5,54)
Malaysia 0,00(0,00–60,62) 0,00(0,00–15,78) 0,00(0,00–11,41) 0,00(0,00–10,48) 0,00(0,00–17,46) 2,78(0,21–37,35) 5,56(0,73–42,38) 3,03(0,40–23,12) 1,28(0,10–17,24)
India 15,09(4,84–47,08) 15,38(4,93–47,99) 34,88(14,90–81,64) 35,71(12,78–99,76) 75,00(29,17–192,70) 27,27(9,28–80,16) 47,62(22,68–99,97) 35,85(16,76–76,66) 38,46(18,32–80,75)
Indonesia 16,15(8,40–31,06) 16,49(7,23–37,64) 23,47(11,73–46,96) 31,11(16,55–58,46) 20,51(10,39–40,48) 16,04(7,19–35,75) 9,60(3,73–24,68) 8,15(3,05–21,78) 7,74(3,01–19,91)
aNepal outbreak in 2013 among a group of Dutch travelers
∞) Cluster of family most probably acquired in a hotel in 2003 in Nigeria
bConfidence interval was not calculated, because the denominator was unknown until 2007–2009
cLatin America constitutes Central and South America, including the Caribbean
dSub-Saharan Africa constitutes Western, Middle, Eastern, and Southern Africa
eThe Arab region constitutes Northern Africa and Western Asia, including Turkey













Table 2 Trends in attack rates (95% confidence interval) for typhoid fever per 100,000 Dutch travelers to (sub) tropical regions from 1997 to 2014 per region/country (Continued)
2006–2008 2007–2009 2008–2010 2009–2011 2010–2012 2011–2013 2012–2014 p value for trend
AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI) AR (95% CI)
All regions 1,04(0,68–1,58) 1,06(0,70–1,60) 1,02(0,67–1,55) 0,88(0,57–1,37) 0,74(0,46–1,19) 0,81(0,51–1,28) 0,87(0,55–1,36) 0.04
Latin Americac 0,17(0,02–1,33) 0,17(0,02–1,32) 0,26(0,05–1,47) 0,18(0,02–1,35) 0,09(0,01–1,27) 0,00(0,00–1,25) 0,00(0,00–1,36) 0.22
Netherlands Antilles 0,00(0,00–3,59) 0,00(0,00–3,17) 0,00(0,00–3,22) 0,00(0,00–2,87) 0,00(0,00–3,22) 0,00(0,00–3,73) 0,00(0,00–4,38)
Surinamb 0.0 0,00(0,00–19,87) 0,00(0,00–17,20) 0,00(0,00–15,78) 0,00(0,00–17,20) 0,00(0,00–31,14) 0,00(0,00–76,77)
Sub-Saharan Africad 1,02(0,22–4,74) 1,06(0,23–4,96) 1,06(0,23–4,94) 1,17(0,29–4,76) 0,65(0,11–3,68) 0,61(0,11–3,48) 0,21(0,02–2,85) 0.04
Arab regione 0,34(0,13–0,89) 0,49(0,23–1,07) 0,51(0,24–1,10) 0,37(0,15–0,89) 0,28(0,10–0,74) 0,23(0,08–0,66) 0,18(0,05–0,59) 0.01
Turkey 0,00(0,00–0,53) 0,00(0,00–0,53) 0,00(0,00–0,52) 0,00(0,00–0,50) 0,00(0,00–0,47) 0,00(0,00–0,47) 0,00(0,00–0,46) 0.009
Morocco 5,17(1,76–15,21) 6,86(2,85–16,52) 6,13(2,47–15,23) 4,74(1,77–12,68) 3,95(1,34–11,61) 3,10(0,93–10,37) 2,42(0,60–9,80) <0.0000001
Asiaf 3,99(2,43–6,55) 4,03(2,40–6,77) 3,37(1,97–5,77) 3,00(1,73–5,20) 2,72(1,55–4,80) 3,47(2,06–5,87)a 4,24(2,61–6,89)a 0.26
Thailand 0,00(0,00–5,16) 0,00(0,00–4,77) 0,00(0,00–4,18) 0,00(0,00–4,07) 0,00(0,00–4,42) 0,00(0,00–5,14) 0,00(0,00–5,65) 0.45
Malaysia 0,00(0,00–12,80) 0,00(0,00–15,36) 0,00(0,00–13,56) 0,00(0,00–12,95) 0,00(0,00–13,24) 1,49(0,11–20,07) 1,75(0,13–23,59) 0.72
India 28,83(12,63–65,77) 36,04(17,16–75,66) 36,70(17,48–77,04) 23,53(11,20–49,40) 20,39(9,88–42,08) 21,93(11,26–42,70) 28,72(15,28–53,97) 0.23













friends and relatives’ [20]. Unfortunately, due to lack of
consistent reporting of demographic characteristics of
cases, the country of birth of a case or the case’s parents
was unknown for the majority of cases, which means it
was mostly unknown whether a case was a tourist or
visiting friends or relatives.
In our study almost 20% of the typhoid cases had been
vaccinated, which demonstrates that the vaccine is not
always effective. A new conjugate vaccine is in development
in India, which could be a good alternative for high risk
travelers in the future [21, 22]. In recent years there have
been a number of reported multi-year outbreaks of
multi-drug resistant typhoid fever [23–26]. Vaccination
against typhoid fever can also prevent infection with
resistant bacteria in travelers at high risk.
Of concern is that the majority of all known VFR cases
were not vaccinated. This suggests that this group is
difficult to reach by travel clinics. It does not say anything
about the protection of the vaccine or the risk of
contracting typhoid fever.
Another limitation is that the number of cases that are
treated for typhoid fever abroad is unknown. Combined
with the possibility of underreporting of cases in the
Netherlands, this could have led to an underestimation
of the calculated ARs. However, this is unlikely to affect
our trend analysis.
Conclusions
We conclude that the overall attack rate of typhoid fever
among Dutch travelers is very low and has declined in
travelers to several countries in the past 20 years despite
a restricted vaccination policy. Attack rates among
Dutch travelers to most countries (except India) continue
to decline and are so low, even in recent periods of
vaccine shortage and temporal restrictions in vaccinations,
that typhoid fever vaccination recommendations can be
further restricted.
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